Categories Uncategorized

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

  • Astrotech subsidiary AgLAB demonstrates the capability of significant improvements in yields for large scale producers of hemp and cannabis CBD-THC oils using breakthrough mass spectrometry technology
  • The company’s AgLAB 1000-D2(TM) mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP(TM)”) allows large-scale distillers to analyze oils during processing, and make real-time adjustments to boost yields and potencies
  • Field trials resulted in improved ending-weight yields by an average of 30%, which can translate into bottom-line profits
  • Astrotech presented the AgLAB Maximum Value Process at last year’s MJBizCon in November, it is the premier global hemp and cannabis business conference and tradeshow

AgLAB, Inc., a subsidiary of Astrotech (NASDAQ: ASTC), has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). AgLAB MVP is designed to improve yields and bottom-line profits for hemp (“CBD”) and cannabis (“THC”) producers of CBD-THC oils by up to 30%.

Large scale CBD and THC oil processors use molecular distillation systems (“MDS”) to produce the valuable oils that are used in lotions, pills, tinctures, and cartridges. Using the AgLAB MVP solution, customers are now able to analyze the oils during processing and make near real-time adjustments that can boost the ending-weight yields and potencies.

“The AgLAB 1000 is a powerful tool for large-scale distillers. This product and method fills a void by providing an easy and accurate real-time analysis that is used to make the right adjustments and improve the yields,” said Joe Levinthal, Chief Science Officer and Master Distiller of AgLAB.

“We are proud to introduce the AgLAB MVP, a breakthrough technology that is more accurate and faster than any other testing method. The AgLAB MVP is very fast and is easy to learn with results that more than pay for itself starting on the first day of use. We believe this is a game changer for the cannabinoid industry and processors must use the AgLAB MVP to stay competitive,” commented Tom Pickens, CEO and CTO of Astrotech.

The AgLAB-1000-D2 mass spectrometer is a ruggedized factory floor analytical instrument designed to quickly and easily analyze complex chemical compounds found in organic plant materials.

About Astrotech Corporation

Astrotech (NASDAQ: ASTC) is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Liquid Biopsy Forecasts Response to Immunotherapy in Lung Cancer Patients

While immunotherapy is revolutionizing cancer therapy, response rates to these novel treatments are low and some patients…

15 hours ago

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production…

1 day ago

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies 

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage…

2 days ago

As Cases of Measles Rise, US Officials Double Down on Contact Tracing and Vaccination

As July came to an end, the United States reached an undesirable milestone: exceeding the…

3 days ago

Climate Change is Accelerating the Spread of Infectious Diseases, Experts Warn

Scientists and public health experts are warning that climate change is accelerating the rate at which infectious…

7 days ago

Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment

Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months…

1 week ago